<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109262</url>
  </required_header>
  <id_info>
    <org_study_id>VAR0147</org_study_id>
    <secondary_id>NCI-2017-00463</secondary_id>
    <secondary_id>39332</secondary_id>
    <nct_id>NCT03109262</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Glass Microspheres PET/CT in Imaging Patients With Liver Tumors</brief_title>
  <official_title>High Quality Imaging and Dosimetry of Yttrium-90 (90Y) SIRT Using a Digital PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies how well yttrium Y 90 glass microspheres positron emission
      tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors. Images
      produced by PET/CT may provide better information about the distribution of particles, such
      as yttrium Y 90 glass microspheres, delivered for selective internal radiation therapy (SIRT)
      compared to the technetium Tc-99m albumin aggregated single photon emission computed
      tomography (SPECT)/CT images.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the image quality of yttrium Y 90 glass microspheres (90Y) PET/CT post SIRT
      images as compared to technetium Tc-99m albumin aggregated (99mTc MAA) SPECT/CT.

      SECONDARY OBJECTIVES:

      I. To determine the superior accuracy in both distribution and dosimetry of 90Y PET/CT post
      SIRT imaging compared to 99mTc MAA planar and SPECT/CT imaging.

      OUTLINE:

      Immediately after standard of care SIRT, patients receive yttrium Y 90 glass microspheres and
      undergo PET/CT over 30 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">February 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image quality of lesions detected with PET/CT assessed by 5-point Likert scale</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Will be compared with the image quality of the lesions seen on the standard of care pre-therapy 99mTc-MAA SPECT/CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiopharmaceutical distribution and dosimetry accuracy of 90Y PET/CT</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Will compare visual distribution discrepancies (if any) and numerical values calculated by SurePlan from both 99mTc MAA SPECT/CT and 90Y PET/CT images. Will use SurePlan software to edge-contour and calculate tumor radiation absorbed dose values in both 99mTc MAA SPECT/CT and 90Y PET/CT images. This software will convert counts/pixel on the images to radiation absorbed dose measure in gray.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Primary Malignant Liver Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (Yttrium Y 90 glass microspheres PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediately after standard of care SIRT, patients receive yttrium Y 90 glass microspheres and undergo PET/CT over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (Yttrium Y 90 glass microspheres PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (Yttrium Y 90 glass microspheres PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Yttrium Y 90 Glass Microspheres</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Diagnostic (Yttrium Y 90 glass microspheres PET/CT)</arm_group_label>
    <other_name>TheraSphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient provides written informed consent

          -  Patient is referred for 90Y SIRT radioembolization of liver tumor(s)

          -  Patient is capable of complying with study procedures

          -  Patient is able to remain still for duration of imaging procedure (approximately 30
             minutes total for digital PET/CT)

        Exclusion Criteria:

          -  Patient is pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Srinivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Iagaru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Risa Jiron</last_name>
    <phone>650-736-1598</phone>
    <email>rjiron@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Risa Jiron</last_name>
      <phone>650-736-1598</phone>
      <email>rjiron@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Shyam Srinivas</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrei Iagaru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

